Call for Presentations, Symposia, and Posters
Updated March 29, 2024
Click here to download the BUPE2024 Abstract Form
Click here to download the BUPE2024 Disclosure Form
Click here to download the BUPE2024 General Release Form
Please email all forms together to jom@pnpco.com. For assistance, contact us at 781-899-2702, ext. 108 or ext. 116 from 9 am – 5 pm ET.
This Virtual Conference is OPEN. We are still recruiting groundbreaking research on this topic!
“BUPE2024 – Buprenorphine in Medicine: Clinical and Public Policy Implications”
This virtual conference will complement the Journal of Opioid Management’s Special Issue on Buprenorphine.
Journal of Opioid Management (JOM) is pleased to present a special conference titled, BUPE2024 – Buprenorphine in Medicine: Clinical and Public Policy Implications on August 5, 2024, focused on all aspects of the use of buprenorphine in medicine. Combined with our soon to be released special issue on this topic, our goal is to broaden the knowledge base on buprenorphine, its potential in the healing pharmacopeia and as a pharmacological tool for pain management and/or addiction.
This unique one day online forum will be comprised of renowned specialists presenting the latest advances in basic science, neurology, clinical application, pharmacology, pharmacogenetics, public health, opioid addiction, ethics, legal, regulatory and compliance. The program is designed to enlighten healthcare providers with new data, essential information, and best practices every medical professional needs to know when caring for patients using buprenorphine.
We request proposals from all areas of research, treatment, ethics, opioid abuse and addiction. Proposals from individuals and panels will be considered. Multidisciplinary panels are encouraged to include perspectives from physicians, nurses, psychologists, basic scientists, pharmacists, etc. Moderators should seek participation from a varied group of faculty with a maximum of four participants per proposal.
We are seeking presentation proposals on the following topics & questions:
· Should buprenorphine be the front-line drug for pain management instead of initially prescribing potentially addictive medications like oxycodone?
· Why is it difficult to get insurance to cover buprenorphine?
· Why is buprenorphine excluded from health insurance formularies of prescription drugs for pain management?
· What is the DEA’s perspective on buprenorphine being excluded from formularies?
· What is the psychiatry community’s perspective on prescribing buprenorphine for addiction treatment?
· What challenges do pharmacists face in filling buprenorphine prescriptions?
· What are the implications of converting patients from buprenorphine treatment to other opioids?
· What is the safest way to wean patients off buprenorphine treatment?
· How does buprenorphine compare to other opioids for pain management and addiction treatment?
· How does buprenorphine compare to other opioids regarding tolerance to achieve the same analgesic effect?
· What are the clinical usages/aspects of buprenorphine? (Clinical pain management vs addiction)
Proposals for previously presented or published work may not be submitted without modification and must be changed or expanded, resulting in a new proposal.
Presentation Proposal Abstract Form and Disclosure Forms are due June 10, 2024. Presentations will be accepted on an ongoing basis, with a finalized presentation deadline of July 8, 2024.
Please note: The moderator is required to include a complete standard format disclosure form as part of the submission. Moderators should contact the speakers named on the proposal to notify them of their inclusion in the submission, and to remind them to complete their disclosure information for inclusion with the
abstract submission.
A complete proposal submission should include the following:
• Presentation title
• A brief description of the presentation, its needs, and rationale for your topic at the BUPE2024 conference.
• Abstract text of up to 200 words, with information about each presenter’s contribution; a focus statement with a succinct description of topics discussed, including background, purpose, procedures and conclusions.
• Educational objectives, goals, and outcomes.
• Five (5) questions for a post-conference test
• Moderator and/or presenter information, including disclosures, bios, and pictures. The presenter’s bio (250-300 words) should include both educational and professional achievements. The bio provided will be published as part of the presentation details. The picture must be a high-resolution .jpg file.
Proposal Notification: Applicants will be notified within two to three (2-3) weeks of abstract submission. All presenters will receive complimentary conference registration. Other details and terms of participation will be communicated to presenters upon acceptance of their proposal.
Presentation Times: Accepted presentations will be recorded and stored on the conference site. Select presentations may be scheduled for presentation live online at a time determined by the presenters and organizers. During the live online presentation, all presenters may respond to questions. After the presentation has been archived and posted on the Virtual website, only the lead presenter or a designate will answer email-based questions. Symposium sessions are 30-60 minutes in length. Panel presentations involving multiple presenters will be given additional time.
Presentation Materials: PowerPoint slides are required and are due within 21 days of acceptance of presentation for content review. MP4 video files can be recorded as soon as content review is complete. PDF handouts of slides will be posted with the video. The session moderator will be expected to assist the organizers in the collection and organization of all presentation slides and handout materials.
Poster Details: Poster submissions may have been previously
presented. Video posters must be original unreleased video and should be no more than 15 minutes in length. Poster presenters
are required to register for the conference.
Submission Details:
-> Please click here to download the BUPE2024 Abstract Form
-> Please Click here for BUPE2024 Disclosure Form (for each individual on abstract form)
-> Please Click here for BUPE2024 General Release Form (for each presenter)
Please email all forms together to jom@pnpco.com. For assistance, contact us at 781-899-2702, ext. 108 or ext. 116 from 9 am – 5 pm ET.